Farmacie pro praxi. 2023;19(3):162-166

Current trends in treatment of atopic dermatitis - a minimum for pharmacists

Petra Brodská

Dermafit Centrum, s. r. o., Plzeň

Atopic dermatitis is a common, chronic, relapsing inflammatory skin disease. The complex of different interactions between individual genetic predisposition to atopic diseases (bronchial asthma, allergic rhino-conjunctivitis, and food or inhalant allergy), environmental factors, epidermal barrier dysfunction and abnormalities of the immune system with predominance Th2 response are involved. Treatment of moderate to severe atopic dermatitis could be challenging. Over the last few years, new advances in the understanding of atopic dermatitis pathogenic mechanisms and inflammatory pathways have led to the identification of specific therapeutic targets and new molecules have been placed on the market (dupilumab, Janus kinase inhibitors - abrocitinib, baricitinib, upadacitinib).

Keywords: atopic dermatitis, topical corticosteroids, topical calcineurin inhibitors, cyclosporine, dupilumab, Janus kinase inhibitors, abrocitinib, baricitinib, upadacitinib.

Accepted: September 21, 2023; Published: October 2, 2023  Show citation